Showing results (1061-1070 of 1,352) with videos related to

Sort By:
Pageof 136
Clinical Pharmacology in Drug Development|January 23, 2025
Effect of Food Intake or Coadministration With an Acid-Reducing Agent on Lenacapavir Pharmacokinetics Following Oral AdministrationRenu Singh, Mark Shelton, Isabel Olson, et al.
Clinical Pharmacology in Drug Development|November 27, 2024
Impact of Acid-Reducing Agents on Sotorasib Pharmacokinetics and Potential Mitigation of the Impact by Coadministration With an Acidic BeveragePanli Cardona, Natasha Strydom, Brett Houk
Clinical Pharmacology in Drug Development|November 26, 2024
Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP-624 in Healthy AdultsGreg Rigdon, Yuki Prescott, John Hall, et al.
Clinical Pharmacology in Drug Development|November 9, 2024
Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation-Positive Advanced Non-Small-Cell Lung Cancer: A Meta-AnalysisMengmeng Zhao, Jian Zhang, Jie Gao, et al.
Clinical Pharmacology in Drug Development|November 14, 2025
Comparative Bioequivalence and Safety Evaluation of Ibuprofen/Phenylephrine Hydrochloride Fixed-Dose Combination Tablets in Healthy Chinese VolunteersMenghan Ye, Rui Zhang, Jing Wan, et al.
Clinical Pharmacology in Drug Development|October 13, 2025
Pharmacokinetics and Bioequivalence of two Empagliflozin Tablet Formulations: Results From a Randomized, Open-Label, Crossover Study in Fasting Healthy VolunteersKar Ming Yee, Elton Sagim, Chuei Wuei Leong, et al.
Clinical Pharmacology in Drug Development|September 27, 2025
The Pathway to Proof-of-Concept for BNC210, a Negative Allosteric Modulator of the Alpha-7 Nicotinic Acetylcholine Receptor (nAChR), for Treatment of Psychiatric DiseasePaul Rolan, Elizabeth Doolin, Dharam Paul, et al.
Clinical Pharmacology in Drug Development|December 27, 2019
A Mass Balance Study of 14 C-Labeled JTZ-951 (Enarodustat), a Novel Orally Available Erythropoiesis-Stimulating Agent, in Patients With End-Stage Renal Disease on HemodialysisSudhakar M Pai, Jeffrey Connaire, Hiroyuki Yamada, et al.
Clinical Pharmacology in Drug Development|December 11, 2019
Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy ParticipantsXiaohua Gong, Borje Darpo, Hongqi Xue, et al.
Clinical Pharmacology in Drug Development|December 12, 2019
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy VolunteersMichael K Badman, Jin Chen, Sachin Desai, et al.
Pageof 136